医学
肠道菌群
肠易激综合征
腹痛
人口
内科学
结肠镜检查
功能性胃肠病
内脏痛
抗生素
队列
队列研究
免疫学
生物
伤害
环境卫生
癌症
受体
结直肠癌
微生物学
作者
Fatemeh Hadizadeh,Ferdinando Bonfiglio,Meriem Belheouane,Marie Vallier,Sascha Sauer,Corinna Bang,Luís Bujanda,Anna Andréasson,Lars Agréus,Lars Engstrand,Nicholas J. Talley,Joseph Rafter,John F. Baines,Susanna Walter,André Franke,Mauro D’Amato
出处
期刊:Gut
[BMJ]
日期:2017-08-01
卷期号:67 (4): 778-779
被引量:45
标识
DOI:10.1136/gutjnl-2017-314792
摘要
We read with great interest the recent communication by Simren et al ,1 reporting a correlation between visceral hypersensitivity and GI symptom severity in functional GI disorders (FGID). Previously, it has been shown that visceral hypersensitivity can be modulated or even induced in animal models, by altering the composition of their gut microbiota with antibiotics or faecal transplantation from IBS donors.2 3 Hence, while a direct link between gut microbiota composition and visceral pain may need to be conclusively established, this holds great potential for translational exploitation in the treatment of IBS and other FGID. Thus far, the potential association between microbiota and abdominal pain in humans has only been investigated in one study that included 15 individuals.4 For this purpose, we studied 159 individuals (average age 59.1, 39.6% men) from the Swedish Population-based Colonoscopy (PopCol) cohort, previously described and with faecal microbiota 16S sequencing data and daily recordings of abdominal pain (number of episodes, duration and intensity) collected over the same period (7.41±7.91 days).5–7 Among these, 52 individuals (assigned to the case group) reported at least one episode …
科研通智能强力驱动
Strongly Powered by AbleSci AI